Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer – A Review

Şerban, Dragoş; Costea, Daniel Ovidiu; Zgură, Anca; Tudosie, M; Dascălu, Ana Maria; Gangura, Gabriel Andrei; Smarandache, Cătălin Gabriel; Sabău, Alexandru Dan; Tudor, Corneliu; Faur, Mihai; Costea, Andreea; Stana, Daniela; Balasescu, Simona Andreea; Tribus, Laura; Tănăsescu, Ciprian

doi:10.21873/invivo.12674

Cited by 11 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Te visual impairments caused by aromatase inhibitors may have been underestimated. Previous studies on their association with anastrozole are scarce and mostly consist of case reports, with dry eye syndrome being a common manifestation, as also refected in the drug label [27]. As anastrozole lowers estrogen levels, some research believe that its use may increase the risk of VMT [28].…”

Section: Discussionmentioning

confidence: 99%

Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment

Li,

Zhao,

Zhu

et al. 2024

International Journal of Clinical Practice

View full text Add to dashboard Cite

Background. Anastrozole has been approved for treatment of hormone receptor-positive advanced or metastatic breast cancer by FDA. This study was to assess Anastrozole-related adverse events (AEs) of real-world through data mining of the US Food and drug administration adverse event reporting system (FAERS). Methods. Four different disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multiitem gamma Poisson shrinker (MGPS) algorithms were employed to quantify the signals of Anastrozole-associated AEs. Results. A total 25 system organ class (SOCs) and 300 significant disproportionality Preferred Terms (PTs) were found in this study. The top 5 most significant SOCs were Eye disorders, renal and urinary disorders, respiratory, thoracic and mediastinal disorders, investigations, and cardiac disorders. Unexpected significant AEs was vitreoretinal traction syndrome (ROR = 1108.22, PRR = 1103.98, IC025 = 9.51, EBGM05 = 389.98), nitrituria (ROR = 3561.82, PRR = 3557.28, IC025 = 10.38, EBGM05 = 318.83) and human epidermal growth factor receptor negative (ROR = 675.04, PRR = 674.01, IC025 = 9, EBGM05 = 204.57). Conclusion. The Unexpected significant AEs associated with anastrozole were identified in this study, warrants urgent clarification through additional prospective studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment

Li,

Zhao,

Zhu

et al. 2024

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Additionally, considering each single aromatase inhibitor, a case of intraepithelial microcysts was reported after the use of exemestane, suggesting a possible drug-induced inhibition on limbal cell function [104], and a possible association between the onset of Sjogren syndrome and anastrozole/letrozole use was documented [105][106][107].…”

Section: Aromatase Inhibitorsmentioning

confidence: 99%

Ocular Surface Side Effects of Novel Anticancer Drugs

Vitiello,

Lixi,

Coco

et al. 2024

Cancers

View full text Add to dashboard Cite

Surgery, anticancer drugs (chemotherapy, hormonal medicines, and targeted treatments), and/or radiation are common treatment strategies for neoplastic diseases. Anticancer drugs eliminate malignant cells through the inhibition of specific pathways that contribute to the formation and development of cancer. Given the ability of such pharmacological medications to combat cancerous cells, their role in the management of neoplastic diseases has become essential. However, these drugs may also lead to undesirable systemic and ocular adverse effects due to cyto/neuro-toxicity and inflammatory reactions. Ocular surface side effects are recognized to significantly impact patient’s quality of life and quality of vision. Blepharoconjunctivitis is known to be a common side effect caused by oxaliplatin, cyclophosphamide, cytarabine, and docetaxel, while anastrozole, methotrexate, and 5-fluorouracil can all determine dry eye disease. However, the potential processes involved in the development of these alterations are yet not fully understood, especially for novel drugs currently available for cancer treatment. This review aims at analyzing the potential ocular surface and adnexal side effects of novel anticancer medications, trying to provide a better understanding of the underlying pharmacological processes and useful insights on the choice of proper management.

show abstract

“…AIs, such as anastrozole and letrozole, have emerged as powerful third-generation options, serving as primary therapies in recent ER-positive breast cancer cases with relatively tolerable side effects compared to earlier treatments. Nevertheless, AIs are not without adverse effects, which include hot flashes, vaginal dryness, osteoporosis, menopausal symptoms, musculoskeletal discomfort, and an elevated risk of bone fractures as long-term consequences (Mortimer, 2010; Serban et al ., 2022). Some cases also report ocular and neuro-retinal impairment (Ağın et al ., 2021).…”

Section: Introductionmentioning

confidence: 99%

Exploring Okra-Derived Compounds as Prospective Aromatase Inhibitors: A Computational Study for Enhanced Breast Cancer Therapy

Lavanya,

Mallur,

Temkar

et al. 2023

Preprint

View full text Add to dashboard Cite

Breast cancer with estrogen receptor positivity represents itself as the most prevalent malignancy among postmenopausal women. One of the promising therapeutic approach involves the use of Aromatase Inhibitors, which competitively bind to aromatase, reducing estrone and estradiol levels. While current drugs have improved survival rates, they are not without adverse effects. Consequently, this study explores the computational screening of medicinally relevant compounds derived from Okra for potential Aromatase Inhibition. Molecular Docking, employing AMDock v1.5.2, was utilized to assess binding affinities with aromatase (PDB:3EQM). Subsequently, in-depth molecular interactions were examined using Discovery Studio Visualizer v4.5, and the stability of docked complexes was evaluated via Molecular Dynamics with the GROMACS package, focusing on RMSD, RMSF, H-bond count, and SASA. The pharmacokinetic properties of the Okra compounds were predicted using admetSAR v2.0. Our findings highlight Quercetin 3-gentiobioside as a standout candidate, demonstrating superior binding affinity (-10 kcal/mol) and an Estimated Ki of 46.77 nM compared to Letrozole and other Okra compounds. Molecular dynamics analysis confirms the stability of Quercetin 3-gentiobioside binding in terms of H-bonds and conformational integrity. In conclusion, our computational investigation identifies Quercetin 3-gentiobioside, along with Quercetin 3-O-rutinoside and Hyperin, as promising candidates for preclinical studies in the pursuit of potential Aromatase Inhibitors.

show abstract

Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer – A Review

Cited by 11 publications

References 44 publications

Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment

Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment

Ocular Surface Side Effects of Novel Anticancer Drugs

Exploring Okra-Derived Compounds as Prospective Aromatase Inhibitors: A Computational Study for Enhanced Breast Cancer Therapy

Contact Info

Product

Resources

About